BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, Holden SN, Benet LZ, Ware JA. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92:203-213. [PMID: 22739140 DOI: 10.1038/clpt.2012.73] [Cited by in Crossref: 179] [Cited by in F6Publishing: 166] [Article Influence: 17.9] [Reference Citation Analysis]
Number Citing Articles
1 Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17:637-58. [DOI: 10.1038/nrc.2017.84] [Cited by in Crossref: 322] [Cited by in F6Publishing: 328] [Article Influence: 64.4] [Reference Citation Analysis]
2 Drenberg CD, Baker SD, Sparreboom A. Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors. Clin Pharmacol Ther 2013;93:215-9. [DOI: 10.1038/clpt.2012.247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
3 Tsujinaka H, Fu J, Shen J, Yu Y, Hafiz Z, Kays J, McKenzie D, Cardona D, Culp D, Peterson W, Gilger BC, Crean CS, Zhang JZ, Kanan Y, Yu W, Cleland JL, Yang M, Hanes J, Campochiaro PA. Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. Nat Commun 2020;11:694. [PMID: 32019921 DOI: 10.1038/s41467-020-14340-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
4 Mullin JM, Schrogie JJ. Drug interactions produced by proton pump inhibitors: not simply a pH effect. Clin Pharmacol Ther 2013;93:150. [PMID: 23169430 DOI: 10.1038/clpt.2012.182] [Reference Citation Analysis]
5 Fink C, Sun D, Wagner K, Schneider M, Bauer H, Dolgos H, Mäder K, Peters SA. Evaluating the Role of Solubility in Oral Absorption of Poorly Water-Soluble Drugs Using Physiologically-Based Pharmacokinetic Modeling. Clin Pharmacol Ther 2020;107:650-61. [PMID: 31608434 DOI: 10.1002/cpt.1672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
6 Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today 2016;21:962-76. [PMID: 26995271 DOI: 10.1016/j.drudis.2016.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
7 van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clin Pharmacokinet. 2017;56:683-688. [PMID: 28101705 DOI: 10.1007/s40262-016-0503-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
8 Ware JA, Dalziel G, Jin JY, Pellett JD, Smelick GS, West DA, Salphati L, Ding X, Sutton R, Fridyland J, Dresser MJ, Morrisson G, Holden SN. Impact of Food and the Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of GDC-0941 in Healthy Volunteers: Bench to Bedside Investigation of pH-Dependent Solubility. Mol Pharmaceutics 2013;10:4074-81. [DOI: 10.1021/mp4005595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
9 Gesenberg C, Mathias NR, Xu Y, Crison J, Savant I, Saari A, Good DJ, Hemenway JN, Narang AS, Schartman RR, Zheng N, Buzescu A, Patel J. Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy. Pharm Res 2019;36. [DOI: 10.1007/s11095-019-2698-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, Brouwers J, Flanagan T, Harwood M, Heinen C, Holm R, Juretschke H, Kubbinga M, Lindahl A, Lukacova V, Münster U, Neuhoff S, Nguyen MA, Peer AV, Reppas C, Hodjegan AR, Tannergren C, Weitschies W, Wilson C, Zane P, Lennernäs H, Langguth P. In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences 2014;57:99-151. [DOI: 10.1016/j.ejps.2014.02.010] [Cited by in Crossref: 166] [Cited by in F6Publishing: 156] [Article Influence: 20.8] [Reference Citation Analysis]
11 Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib. European Journal of Pharmaceutical Sciences 2015;76:203-12. [DOI: 10.1016/j.ejps.2015.05.013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
12 Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 2013;10:4055-62. [PMID: 24044612 DOI: 10.1021/mp400403s] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 9.7] [Reference Citation Analysis]
13 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 27.0] [Reference Citation Analysis]
14 Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol 2021;14:1329-44. [PMID: 34491123 DOI: 10.1080/17512433.2021.1978288] [Reference Citation Analysis]
15 Gazzé G. Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. Melanoma Manag 2018;5:MMT07. [PMID: 30459938 DOI: 10.2217/mmt-2017-0026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
16 Jede C, Wagner C, Kubas H, Weber C, Weigandt M, Koziolek M, Weitschies W. Automated small-scale in vitro transfer model as screening tool for the prediction of in vivo-dissolution and precipitation of poorly solubles. Int J Pharm 2019;556:150-8. [PMID: 30553006 DOI: 10.1016/j.ijpharm.2018.12.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
17 Matsui K, Tsume Y, Amidon GE, Amidon GL. In Vitro Dissolution of Fluconazole and Dipyridamole in Gastrointestinal Simulator (GIS), Predicting in Vivo Dissolution and Drug–Drug Interaction Caused by Acid-Reducing Agents. Mol Pharmaceutics 2015;12:2418-28. [DOI: 10.1021/acs.molpharmaceut.5b00135] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
18 Ramos H, Soares MIL, Silva J, Raimundo L, Calheiros J, Gomes C, Reis F, Monteiro FA, Nunes C, Reis S, Bosco B, Piazza S, Domingues L, Chlapek P, Vlcek P, Fabian P, Rajado AT, Carvalho ATP, Veselska R, Inga A, Pinho E Melo TMVD, Saraiva L. A selective p53 activator and anticancer agent to improve colorectal cancer therapy. Cell Rep 2021;35:108982. [PMID: 33852837 DOI: 10.1016/j.celrep.2021.108982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 More MP, Deshmukh PK. Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis. Drug Deliv Transl Res 2020;10:862-77. [PMID: 32103449 DOI: 10.1007/s13346-020-00729-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
20 Nguyen L, Holland J, Mamelok R, Laberge M, Grenier J, Swearingen D, Armas D, Lacy S. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol 2015;55:1293-302. [DOI: 10.1002/jcph.526] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
21 Litou C, Effinger A, Kostewicz ES, Box KJ, Fotaki N, Dressman JB. Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review. Journal of Pharmacy and Pharmacology 2019;71:643-73. [DOI: 10.1111/jphp.12983] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 2015;41:412-22. [PMID: 25818541 DOI: 10.1016/j.ctrv.2015.03.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
23 Chiang P, Nagapudi K, Liu J, Crawford JJ, Zbieg JR, Plise E, Deng Y. An Integrated Analysis of Solid Form Change Impact on Solubility and Permeability: Case Study of Oral Exposure in Rats of an RAR Related Orphan Receptor C Inhibitor. Journal of Pharmaceutical Sciences 2019;108:2256-63. [DOI: 10.1016/j.xphs.2019.01.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 Sorich MJ, Mutlib F, Dyk M, Hopkins AM, Polasek TM, Marshall J, Rodrigues AD, Rowland A. Use of Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Axitinib Exposure: A Fresh Approach to Precision Dosing in Oncology. The Journal of Clinical Pharmacology 2019;59:872-9. [DOI: 10.1002/jcph.1377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 Yago MR, Frymoyer A, Benet LZ, Smelick GS, Frassetto LA, Ding X, Dean B, Salphati L, Budha N, Jin JY, Dresser MJ, Ware JA. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J 2014;16:1358-65. [PMID: 25274610 DOI: 10.1208/s12248-014-9673-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
26 Seminerio MJ, Ratain MJ. Preventing adverse drug-drug interactions: a need for improved data and logistics. Mayo Clin Proc 2013;88:126-8. [PMID: 23374616 DOI: 10.1016/j.mayocp.2012.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Ks NS, K GP, Verma R, Ananthakrishna P, Kumar L. Validation of HPLC Method for Quantitative Determination of Gefitinib in Polymeric Nanoformulation. Pharm Chem J 2017;51:159-63. [DOI: 10.1007/s11094-017-1575-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
28 Dong Z, Li J, Wu F, Zhao P, Lee SC, Zhang L, Seo P, Zhang L. Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug-Drug Interactions for Weak Base Drugs. CPT Pharmacometrics Syst Pharmacol 2020;9:456-65. [PMID: 32633893 DOI: 10.1002/psp4.12541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
29 Bardoliwala D, Javia A, Ghosh S, Misra A, Sawant K. Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment. Ther Deliv 2021;12:397-418. [PMID: 33902294 DOI: 10.4155/tde-2020-0101] [Reference Citation Analysis]
30 Tóth G, Jánoska Á, Szabó Z, Völgyi G, Orgován G, Szente L, Noszál B. Physicochemical characterisation and cyclodextrin complexation of erlotinib. Supramolecular Chemistry 2016;28:656-64. [DOI: 10.1080/10610278.2015.1117083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
31 Sun W, Klamerus KJ, Yuhas LM, Pawlak S, Plotka A, O'Gorman M, Kirkovsky L, Kosa M, Wang D. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions. Clin Pharmacol Drug Dev 2017;6:614-26. [PMID: 28430398 DOI: 10.1002/cpdd.356] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
32 Gougis P, Palmieri LJ, Funck-Brentano C, Paci A, Flippot R, Mir O, Coriat R. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Crit Rev Oncol Hematol 2019;141:112-24. [PMID: 31276964 DOI: 10.1016/j.critrevonc.2019.06.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Ware JA, Dalziel G. Physical chemical drug-drug interactions from drug discovery to registration: new opportunities for the pharmaceutical scientist to impact drug development. Mol Pharm 2013;10:3967-9. [PMID: 24491029 DOI: 10.1021/mp4005639] [Reference Citation Analysis]
34 Hosey CM, Chan R, Benet LZ. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. AAPS J 2016;18:251-60. [PMID: 26589308 DOI: 10.1208/s12248-015-9845-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
35 Shao J, Markowitz JS, Bei D, An G. Enzyme-Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors. Journal of Pharmaceutical Sciences 2014;103:3810-33. [DOI: 10.1002/jps.24113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
36 Jede C, Wagner C, Kubas H, Weber C, Weigandt M, Koziolek M, Weitschies W. Application of an automated small-scale in vitro transfer model to predict in vivo precipitation inhibition. International Journal of Pharmaceutics 2019;565:458-71. [DOI: 10.1016/j.ijpharm.2019.05.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Jung D, Han JM, Yee J, Kim JY, Gwak HS. Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. Med Oncol 2018;35. [DOI: 10.1007/s12032-018-1213-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
38 Zhao D, Chen J, Chu M, Long X, Wang J. Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. Drug Des Devel Ther 2020;14:1663-81. [PMID: 32431491 DOI: 10.2147/DDDT.S249098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
39 Boegemann M, Schlack K, Rink M, Bernhardt S, Moran M, Hubbe M, Bergmann L, Schmid M, Strauss A. Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncol 2020;16:2939-48. [PMID: 33021843 DOI: 10.2217/fon-2020-0548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Fang YH, Yang YH, Hsieh MJ, Hung MS, Lin YC. Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res 2019;11:8539-46. [PMID: 31572008 DOI: 10.2147/CMAR.S222278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR, Sawyer MB. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients. Clin Colorectal Cancer 2016;15:257-63. [PMID: 26803708 DOI: 10.1016/j.clcc.2015.12.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
42 Fagiolino P, Vázquez M, Ibarra M, Maldonado C, Eiraldi R. Drug-Drug and Food-Drug Interactions of Pharmacokinetic Nature. In: Talevi A, Quiroga PAM, editors. ADME Processes in Pharmaceutical Sciences. Cham: Springer International Publishing; 2018. pp. 271-99. [DOI: 10.1007/978-3-319-99593-9_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
44 Sasaki M, Aoyama T, Sugawara M, Takekuma Y. Influence of gastrointestinal activity on the absorption of nilotinib. Drug Metabolism and Pharmacokinetics 2020;35:102-10. [DOI: 10.1016/j.dmpk.2019.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Kim A, Chung I, Yoon SH, Yu KS, Lim KS, Cho JY, Lee H, Jang IJ, Chung JY. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics. Drug Metab Dispos 2014;42:1174-9. [PMID: 24764147 DOI: 10.1124/dmd.113.055616] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
46 Zhang L, Wu F, Lee SC, Zhao H, Zhang L. pH-Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development. Clin Pharmacol Ther 2014;96:266-77. [DOI: 10.1038/clpt.2014.87] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
47 Sharma M, Holmes HM, Mehta HB, Chen H, Aparasu RR, Shih YT, Giordano SH, Johnson ML. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 2019;125:1155-62. [PMID: 30605231 DOI: 10.1002/cncr.31917] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
48 Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, Shi M. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol 2017;79:1119-28. [PMID: 28424965 DOI: 10.1007/s00280-017-3308-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
49 Mathias NR, Xu Y, Patel D, Grass M, Caldwell B, Jager C, Mullin J, Hansen L, Crison J, Saari A, Gesenberg C, Morrison J, Vig B, Raghavan K. Assessing the Risk of pH-Dependent Absorption for New Molecular Entities: A Novel in Vitro Dissolution Test, Physicochemical Analysis, and Risk Assessment Strategy. Mol Pharmaceutics 2013;10:4063-73. [DOI: 10.1021/mp400426f] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
50 Jafari H, Atlasi Z, Mahdavinia GR, Hadifar S, Sabzi M. Magnetic κ-carrageenan/chitosan/montmorillonite nanocomposite hydrogels with controlled sunitinib release. Mater Sci Eng C Mater Biol Appl 2021;124:112042. [PMID: 33947542 DOI: 10.1016/j.msec.2021.112042] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Cheng V, Lemos MD, Hunter N, Badry N, Lemos JD. Concomitant use of capecitabine and proton pump inhibitors – Is it safe? J Oncol Pharm Pract 2019;25:1705-11. [DOI: 10.1177/1078155219846952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
52 Kola Srinivas NS, Verma R, Pai Kulyadi G, Kumar L. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization. Int J Nanomedicine 2017;12:15-28. [PMID: 28031710 DOI: 10.2147/IJN.S122729] [Cited by in Crossref: 40] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
53 Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R. Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 2021;6:100231. [PMID: 34509802 DOI: 10.1016/j.esmoop.2021.100231] [Reference Citation Analysis]
54 Patel CG, Rangachari L, Patti M, Griffin C, Shou Y, Venkatakrishnan K. Characterizing the Sources of Pharmacokinetic Variability for TAK-117 (Serabelisib), an Investigational Phosphoinositide 3-Kinase Alpha Inhibitor: A Clinical Biopharmaceutics Study to Inform Development Strategy. Clinical Pharmacology in Drug Development 2019;8:637-46. [DOI: 10.1002/cpdd.613] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
55 Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E, Djebli N, Meneses-Lorente G. Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib. AAPS J 2020;22:78. [PMID: 32458089 DOI: 10.1208/s12248-020-00463-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
56 Levêque D, Duval C, Poulat C, Palas B, El Aatmani A, Dory A, Becker G, Gourieux B. Mécanismes des interactions pharmacocinétiques impliquant les agents anticancéreux oraux. Bulletin du Cancer 2015;102:65-72. [DOI: 10.1016/j.bulcan.2014.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
57 Chung JI, Kelly RC, Wahlstrom J, Wu B, Wu T, Alvarez-Nunez F. Maximizing the Impact of Physiologically Based Oral Absorption Modeling and Simulation. J Pharm Sci 2017;106:734-7. [PMID: 27915208 DOI: 10.1016/j.xphs.2016.11.015] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
58 Stein J, Mann J. Specialty pharmacy services for patients receiving oral medications for solid tumors. American Journal of Health-System Pharmacy 2016;73:775-96. [DOI: 10.2146/ajhp150863] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Koziolek M, Grimm M, Bollmann T, Schäfer KJ, Blattner SM, Lotz R, Boeck G, Weitschies W. Characterization of the GI transit conditions in Beagle dogs with a telemetric motility capsule. European Journal of Pharmaceutics and Biopharmaceutics 2019;136:221-30. [DOI: 10.1016/j.ejpb.2019.01.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
60 Lennernäs H. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Mol Pharm 2014;11:12-23. [PMID: 24206063 DOI: 10.1021/mp4003392] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
61 Gala UH, Miller DA, Williams RO 3rd. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Rev Cancer 2020;1873:188319. [PMID: 31678141 DOI: 10.1016/j.bbcan.2019.188319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
62 Li J, Tsinman K, Tsinman O, Wigman L. Using pH Gradient Dissolution with In-Situ Flux Measurement to Evaluate Bioavailability and DDI for Formulated Poorly Soluble Drug Products. AAPS PharmSciTech 2018;19:2898-907. [PMID: 30209787 DOI: 10.1208/s12249-018-1164-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
63 van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34:1309-14. [PMID: 26858332 DOI: 10.1200/JCO.2015.65.2560] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 11.3] [Reference Citation Analysis]
64 Wang Y, Cheng J, Zhao D, Liu Y, Luo T, Zhong Y, Mo F, Kong X, Song J. Designed DNA nanostructure grafted with erlotinib for non-small-cell lung cancer therapy. Nanoscale 2020;12:23953-8. [DOI: 10.1039/d0nr06945k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
65 Song HJ, Rhew K, Lee YJ, Ha IH. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol 2021;26:34-50. [PMID: 33089416 DOI: 10.1007/s10147-020-01795-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017;3:767-773. [PMID: 27737436 DOI: 10.1001/jamaoncol.2016.3358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
67 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
69 Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Liu SF, Huang KT, Chen HC, Chang YC, Lin MC. Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One 2016;11:e0149722. [PMID: 26894507 DOI: 10.1371/journal.pone.0149722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
70 Loisios-Konstantinidis I, Dressman J. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities. Mol Pharm 2021;18:1-17. [PMID: 33320002 DOI: 10.1021/acs.molpharmaceut.0c00903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
71 de Koning BAE, Mooij M, Johnson TN, de Wildt SN. Developmental Changes in the Processes Governing Oral Drug Absorption. In: Bar-shalom D, Rose K, editors. Pediatric Formulations. New York: Springer; 2014. pp. 25-42. [DOI: 10.1007/978-1-4899-8011-3_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
72 Han JM, Han HW, Yee J, Kim MK, Moon JY, Cho S, Jung D, Cho YS, Seo I, Kim JY, Gwak HS. Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study. Eur J Clin Pharmacol 2020;76:1183-91. [PMID: 32444938 DOI: 10.1007/s00228-020-02897-x] [Reference Citation Analysis]
73 Jede C, Wagner C, Kubas H, Weigandt M, Weber C, Lecomte M, Badolo L, Koziolek M, Weitschies W. Improved Prediction of in Vivo Supersaturation and Precipitation of Poorly Soluble Weakly Basic Drugs Using a Biorelevant Bicarbonate Buffer in a Gastrointestinal Transfer Model. Mol Pharm 2019;16:3938-47. [PMID: 31335153 DOI: 10.1021/acs.molpharmaceut.9b00534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
74 Shen Y, TanTai J. Co-Delivery Anticancer Drug Nanoparticles for Synergistic Therapy Against Lung Cancer Cells. Drug Des Devel Ther 2020;14:4503-10. [PMID: 33122893 DOI: 10.2147/DDDT.S275123] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Huh KY, Hwang S, Park SY, Lim HJ, Jin M, Oh J, Yu KS, Chung JY. Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib. Pharmaceutics 2021;13:629. [PMID: 33925058 DOI: 10.3390/pharmaceutics13050629] [Reference Citation Analysis]
76 Faber KP, Wu HF, Yago MR, Xu X, Kadiyala P, Frassetto LA, Benet LZ. Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption. Pharm Res 2017;34:619-28. [PMID: 28028768 DOI: 10.1007/s11095-016-2090-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
77 Peters S, Zimmermann S, Adjei AA. Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. Cancer Treatment Reviews 2014;40:917-26. [DOI: 10.1016/j.ctrv.2014.06.010] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis]
78 Zhang L, Fan C, Guo Z, Li Y, Zhao S, Yang S, Yang Y, Zhu J, Lin D. Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer. European Journal of Medicinal Chemistry 2013;69:833-41. [DOI: 10.1016/j.ejmech.2013.09.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
79 Rassy E, Cerbone L, Auclin E, Benchimoll-Zouari A, Flippot R, Alves Costa Silva C, Colomba E, Geraud A, Guida A, Mir O, Combarel D, Paci A, Escudier B, Albiges L. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. Oncologist 2021;26:389-96. [PMID: 33554383 DOI: 10.1002/onco.13711] [Reference Citation Analysis]
80 Yago MR, Frymoyer AR, Smelick GS, Frassetto LA, Budha NR, Dresser MJ, Ware JA, Benet LZ. Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Mol Pharm 2013;10:4032-7. [PMID: 23980906 DOI: 10.1021/mp4003738] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
81 Arora JS, Murad HY, Ashe S, Halliburton G, Yu H, He J, John VT, Khismatullin DB. Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro. Mol Pharm 2016;13:3080-90. [PMID: 27383214 DOI: 10.1021/acs.molpharmaceut.6b00216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
82 Wan X, Zheng X, Pang X, Zhang Z, Zhang Q. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer. Colloids and Surfaces B: Biointerfaces 2015;136:817-27. [DOI: 10.1016/j.colsurfb.2015.10.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
83 He S, Bian J, Shao Q, Zhang Y, Hao X, Luo X, Feng Y, Huang L. Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics. Front Pharmacol 2021;12:797881. [PMID: 34938198 DOI: 10.3389/fphar.2021.797881] [Reference Citation Analysis]
84 Mammatas LH, Zandvliet AS, Rovithi M, Honeywell RJ, Swart EL, Peters GJ, Menke-van der Houven van Oordt CW, Verheul HMW. Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study. Cancer Chemother Pharmacol 2020;85:931-40. [PMID: 32274565 DOI: 10.1007/s00280-020-04065-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
85 Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci 2014;57:152-63. [PMID: 24486482 DOI: 10.1016/j.ejps.2014.01.009] [Cited by in Crossref: 141] [Cited by in F6Publishing: 119] [Article Influence: 17.6] [Reference Citation Analysis]
86 Rowland A, van Dyk M, Mangoni AA, Miners JO, Mckinnon RA, Wiese MD, Rowland A, Kichenadasse G, Gurney H, Sorich MJ. Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. Expert Opinion on Drug Metabolism & Toxicology 2016;13:31-49. [DOI: 10.1080/17425255.2016.1229303] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
87 Planchard D. Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib? J Clin Oncol 2016;34:1292-4. [PMID: 26976417 DOI: 10.1200/JCO.2015.66.3344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
88 Yu G, Zheng Y, Yu Y, Li GF, Derendorf H. Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. Drug Discov Today 2019;24:845-57. [PMID: 30648608 DOI: 10.1016/j.drudis.2019.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
89 Kumarakulasinghe NB, Syn N, Soon YY, Asmat A, Zheng H, Loy EY, Pang B, Soo RA. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget 2016;7:85542-50. [PMID: 27907909 DOI: 10.18632/oncotarget.13458] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
90 Hussaarts KGAM, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol 2019;11:1758835918818347. [PMID: 30643582 DOI: 10.1177/1758835918818347] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
91 Zhou X, Pant S, Nemunaitis J, Craig Lockhart A, Falchook G, Bauer TM, Patel M, Sarantopoulos J, Bargfrede M, Muehler A, Rangachari L, Zhang B, Venkatakrishnan K. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Invest New Drugs 2018;36:248-58. [PMID: 28852909 DOI: 10.1007/s10637-017-0499-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
92 Laille E, Savona MR, Scott BL, Boyd TE, Dong Q, Skikne B. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies: The Journal of Clinical Pharmacology. The Journal of Clinical Pharmacology 2014;54:630-9. [DOI: 10.1002/jcph.251] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
93 Miyazaki K, Sato S, Kodama T, Tamura T, Kagohashi K, Satoh H, Hizawa N. Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer. Mol Clin Oncol 2016;4:873-7. [PMID: 27123299 DOI: 10.3892/mco.2016.810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 2013;52:593-609. [PMID: 23532985 DOI: 10.1007/s40262-013-0058-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 7.5] [Reference Citation Analysis]
95 Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, Csajka C, Widmer N. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. Ther Drug Monit 2020;42:33-44. [PMID: 31479043 DOI: 10.1097/FTD.0000000000000699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
96 Dodd S, Kollipara S, Sanchez-felix M, Kim H, Meng Q, Beato S, Heimbach T. Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface. Journal of Pharmaceutical Sciences 2019;108:87-101. [DOI: 10.1016/j.xphs.2018.10.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
97 Wu CY, Ho HJ, Wu CY, Chen YJ, Lee TY, Hsu YC, Lin JT. Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor. Gut 2020:gutjnl-2020-321932. [PMID: 32907829 DOI: 10.1136/gutjnl-2020-321932] [Reference Citation Analysis]
98 Kim JS, Han JM, Cho YS, Choi KH, Gwak HS. Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib. Molecules 2021;26:3300. [PMID: 34072626 DOI: 10.3390/molecules26113300] [Reference Citation Analysis]
99 Mitra A, Parrott N, Miller N, Lloyd R, Tistaert C, Heimbach T, Ji Y, Kesisoglou F. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies. Journal of Pharmaceutical Sciences 2020;109:1380-94. [DOI: 10.1016/j.xphs.2019.11.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
100 Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 2019;9:18202. [PMID: 31796841 DOI: 10.1038/s41598-019-54804-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
101 Zhou Q, Fu Z. In vitro and in vivo Study of a Novel Liposome-Mediated Dual Drug Delivery for Synergistic Lung Cancer Therapy via Oral Administration. Onco Targets Ther 2020;13:12695-703. [PMID: 33328741 DOI: 10.2147/OTT.S276837] [Reference Citation Analysis]
102 Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Mol Pharm 2018;15:5678-96. [PMID: 30376336 DOI: 10.1021/acs.molpharmaceut.8b00858] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
103 Aburub A, Fischer M, Camilleri M, Semler JR, Fadda HM. Comparison of pH and motility of the small intestine of healthy subjects and patients with symptomatic constipation using the wireless motility capsule. Int J Pharm. 2018;544:158-164. [PMID: 29678546 DOI: 10.1016/j.ijpharm.2018.04.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
104 Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014;89:179-96. [PMID: 24041628 DOI: 10.1016/j.critrevonc.2013.08.007] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
105 Zhou J, Quinlan M, Glenn K, Boss H, Picard F, Castro H, Sellami D. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers. Br J Clin Pharmacol 2016;82:1022-9. [PMID: 27277189 DOI: 10.1111/bcp.13038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
106 Terada T, Noda S, Inui K. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther. 2015;152:125-134. [PMID: 25976912 DOI: 10.1016/j.pharmthera.2015.05.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 6.7] [Reference Citation Analysis]
107 Morcos PN, Guerini E, Parrott N, Dall G, Blotner S, Bogman K, Sturm C, Balas B, Martin-Facklam M, Phipps A. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects. Clin Pharmacol Drug Dev 2017;6:388-97. [PMID: 27545320 DOI: 10.1002/cpdd.296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
108 van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:e315-26. [PMID: 24988935 DOI: 10.1016/S1470-2045(13)70579-5] [Cited by in Crossref: 124] [Cited by in F6Publishing: 56] [Article Influence: 15.5] [Reference Citation Analysis]
109 McKelvey CA, Kesisoglou F. Enabling an HCV Treatment Revolution and the Frontiers of Solid Solution Formulation. J Pharm Sci 2019;108:50-7. [PMID: 30439459 DOI: 10.1016/j.xphs.2018.11.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
110 Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10-i19. [PMID: 29462254 DOI: 10.1093/annonc/mdx703] [Cited by in Crossref: 157] [Cited by in F6Publishing: 160] [Article Influence: 52.3] [Reference Citation Analysis]
111 de Jong J, Haddish-Berhane N, Hellemans P, Jiao J, Sukbuntherng J, Ouellet D. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure. Cancer Chemother Pharmacol 2018;82:299-308. [PMID: 29882017 DOI: 10.1007/s00280-018-3613-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Keller KL, Franquiz MJ, Duffy AP, Trovato JA. Drug–drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 2018;24:110-5. [DOI: 10.1177/1078155216682311] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
113 Saito Y, Takekuma Y, Kobayashi M, Shinagawa N, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K, Sugawara M. Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol 2021;77:381-8. [PMID: 33029650 DOI: 10.1007/s00228-020-03013-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Giri N, Lam LH, LaBadie RR, Krzyzaniak JF, Jiang H, Hee B, Liang Y, Shaik MN. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. Cancer Chemother Pharmacol 2017;80:1249-60. [PMID: 29086063 DOI: 10.1007/s00280-017-3472-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
115 Auch C, Jede C, Harms M, Wagner C, Mäder K. Impact of amorphization and GI physiology on supersaturation and precipitation of poorly soluble weakly basic drugs using a small-scale in vitro transfer model. Int J Pharm 2020;574:118917. [PMID: 31811926 DOI: 10.1016/j.ijpharm.2019.118917] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
116 Koziolek M, Schneider F, Grimm M, Modeβ C, Seekamp A, Roustom T, Siegmund W, Weitschies W. Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies. Journal of Controlled Release 2015;220:71-8. [DOI: 10.1016/j.jconrel.2015.10.022] [Cited by in Crossref: 78] [Cited by in F6Publishing: 65] [Article Influence: 11.1] [Reference Citation Analysis]
117 Moon JY, Han JM, Seo I, Gwak HS. Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity. Breast Cancer Res Treat 2019;178:239-44. [PMID: 31372791 DOI: 10.1007/s10549-019-05382-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
118 Marcath LA, Finley CM, Wong SF, Hertz DL. Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy. BMC Cancer 2021;21:324. [PMID: 33771105 DOI: 10.1186/s12885-021-08050-w] [Reference Citation Analysis]
119 Musib L, Choo E, Deng Y, Eppler S, Rooney I, Chan IT, Dresser MJ. Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects. Mol Pharm 2013;10:4046-54. [PMID: 24010577 DOI: 10.1021/mp400383x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
120 Kovacevic T, Kovacevic SV, Stanetic M, Kovacevic P, Miljkovic B. Impact of pharmacist's intervention on decreasing erlotinib interactions in the treatment of lung cancer patients in low resource settings. J Oncol Pharm Pract 2021;27:350-8. [PMID: 32349642 DOI: 10.1177/1078155220921545] [Reference Citation Analysis]
121 Ou YC, Liu L, Tariq B, Wang K, Jindal A, Tang Z, Gao Y, Sahasranaman S. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies. Clin Transl Sci 2021;14:764-72. [PMID: 33306268 DOI: 10.1111/cts.12948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
122 Hu X, Lou H, Hageman MJ. Preparation of lapatinib ditosylate solid dispersions using solvent rotary evaporation and hot melt extrusion for solubility and dissolution enhancement. International Journal of Pharmaceutics 2018;552:154-63. [DOI: 10.1016/j.ijpharm.2018.09.062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
123 Sim W, Jain SR, Lim WH, Chin YH, Ng CH, Syn N, Goh KS, Soo R, Wang L, Goh BC. Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:3567-81. [PMID: 34584857 DOI: 10.21037/tlcr-21-378] [Reference Citation Analysis]
124 Chu MP, Ghosh S, Chambers CR, Basappa N, Butts CA, Chu Q, Fenton D, Joy AA, Sangha R, Smylie M, Sawyer MB. Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 2015;16:33-9. [PMID: 25246385 DOI: 10.1016/j.cllc.2014.07.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
125 Chung J, Alvarez-nunez F, Chow V, Daurio D, Davis J, Dodds M, Emery M, Litwiler K, Paccaly A, Peng J, Rock B, Wienkers L, Yang C, Yu Z, Wahlstrom J. Utilizing Physiologically Based Pharmacokinetic Modeling to Inform Formulation and Clinical Development for a Compound with pH-Dependent Solubility. Journal of Pharmaceutical Sciences 2015;104:1522-32. [DOI: 10.1002/jps.24339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
126 Sohail MF, Rehman M, Sarwar HS, Naveed S, Salman O, Bukhari NI, Hussain I, Webster TJ, Shahnaz G. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine 2018;13:3145-61. [PMID: 29922053 DOI: 10.2147/IJN.S164518] [Cited by in Crossref: 48] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
127 Indini A, Petrelli F, Tomasello G, Rijavec E, Facciorusso A, Grossi F, Ghidini M. Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020;12. [PMID: 32325628 DOI: 10.3390/cancers12040998] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
128 Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol 2017;80:497-505. [PMID: 28702772 DOI: 10.1007/s00280-017-3375-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
129 Matsumura N, Ono A, Akiyama Y, Fujita T, Sugano K. Bottom-Up Physiologically Based Oral Absorption Modeling of Free Weak Base Drugs. Pharmaceutics 2020;12:E844. [PMID: 32899235 DOI: 10.3390/pharmaceutics12090844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
130 Gay C, Toulet D, Le Corre P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy: Pharmacokinetic interactions of TKIs. Hematological Oncology 2017;35:259-80. [DOI: 10.1002/hon.2335] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
131 Rogala BG, Charpentier MM, Nguyen MK, Landolf KM, Hamad L, Gaertner KM. Oral Anticancer Therapy: Management of Drug Interactions. J Oncol Pract 2019;15:81-90. [PMID: 30763198 DOI: 10.1200/JOP.18.00483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 5.5] [Reference Citation Analysis]
132 Wang L, Subasic C, Minchin RF, Kaminskas LM. Drug formulation and nanomedicine approaches to targeting lymphatic cancer metastases. Nanomedicine (Lond) 2019;14:1605-21. [PMID: 31166140 DOI: 10.2217/nnm-2018-0478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
133 Mathijssen RHJ, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 2014;11:272-81. [DOI: 10.1038/nrclinonc.2014.40] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 12.3] [Reference Citation Analysis]
134 Lu T, Fraczkiewicz G, Salphati L, Budha N, Dalziel G, Smelick GS, Morrissey KM, Davis JD, Jin JY, Ware JA. Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics. CPT Pharmacometrics Syst Pharmacol 2017;6:747-55. [PMID: 28748626 DOI: 10.1002/psp4.12228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
135 Tiwari A, Gupta VG, Bakhshi S. Newer medical therapies for metastatic soft tissue sarcoma. Expert Rev Anticancer Ther 2017;17:257-70. [PMID: 28103739 DOI: 10.1080/14737140.2017.1285229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
136 Agrawal S, Dwivedi M, Ahmad H, Chadchan SB, Arya A, Sikandar R, Kaushik S, Mitra K, Jha RK, Dwivedi AK. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer. Nanomedicine. 2018;14:327-337. [PMID: 29129754 DOI: 10.1016/j.nano.2017.10.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
137 Pang J, Dalziel G, Dean B, Ware JA, Salphati L. Pharmacokinetics and Absorption of the Anticancer Agents Dasatinib and GDC-0941 under Various Gastric Conditions in Dogs – Reversing the Effect of Elevated Gastric pH with Betaine HCl. Mol Pharmaceutics 2013;10:4024-31. [DOI: 10.1021/mp400356m] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
138 Yang Z, Shao D, Zhou G. Dissolution behavior and thermodynamic properties of lapatinib ditosylate in pure and mixed organic solvents from T = (283.15–323.15) K. Fluid Phase Equilibria 2019;486:91-7. [DOI: 10.1016/j.fluid.2019.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
139 Huang L, Xu AM, Li TJ, Han WX, Xu J. Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients? World J Gastroenterol 2014; 20(22): 6981-6988 [PMID: 24944492 DOI: 10.3748/wjg.v20.i22.6981] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
140 Fischer M, Siva S, Wo JM, Fadda HM. Assessment of Small Intestinal Transit Times in Ulcerative Colitis and Crohn's Disease Patients with Different Disease Activity Using Video Capsule Endoscopy. AAPS PharmSciTech. 2017;18:404-409. [PMID: 27032935 DOI: 10.1208/s12249-016-0521-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
141 Pepin XJ, Moir AJ, Mann JC, Sanderson NJ, Barker R, Meehan E, Plumb AP, Bailey GR, Murphy DS, Krejsa CM, Andrew MA, Ingallinera TG, Slatter JG. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices. European Journal of Pharmaceutics and Biopharmaceutics 2019;142:435-48. [DOI: 10.1016/j.ejpb.2019.07.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
142 Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR. Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 2015;21:194-200. [DOI: 10.1177/1078155214527145] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
143 Gillis NK, McLeod HL. The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat 2016;28:28-42. [PMID: 27620953 DOI: 10.1016/j.drup.2016.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
144 Lucas CJ, Martin JH. Pharmacokinetic-Guided Dosing of New Oral Cancer Agents. The Journal of Clinical Pharmacology 2017;57:S78-98. [DOI: 10.1002/jcph.937] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
145 Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Inherent formulation issues of kinase inhibitors. J Control Release 2016;239:118-27. [PMID: 27578098 DOI: 10.1016/j.jconrel.2016.08.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
146 Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 2014;57:300-21. [PMID: 24060672 DOI: 10.1016/j.ejps.2013.09.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 160] [Article Influence: 21.0] [Reference Citation Analysis]
147 Surofchy DD, Frassetto LA, Benet LZ. Food, Acid Supplementation and Drug Absorption - a Complicated Gastric Mix: a Randomized Control Trial. Pharm Res 2019;36:155. [PMID: 31485804 DOI: 10.1007/s11095-019-2693-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Shrivastava R, Trivedi S, Singh PK, Asif M, Chourasia MK, Khanna A, Bhadauria S. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity. Biochemical and Biophysical Research Communications 2018;503:677-83. [DOI: 10.1016/j.bbrc.2018.06.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
149 Miller BE, Smart K, Mistry S, Ambery CL, Bloomer JC, Connolly P, Sanderson D, Shreeves T, Smith R, Lazaar AL. The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 2014;39:173-81. [PMID: 24504700 DOI: 10.1007/s13318-014-0179-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
150 Wan X, Zheng X, Pang X, Zhang Z, Jing T, Xu W, Zhang Q. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. Int J Pharm 2015;484:16-28. [PMID: 25700543 DOI: 10.1016/j.ijpharm.2015.02.037] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
151 Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Eur J Pharm Biopharm 2019;136:120-30. [PMID: 30660696 DOI: 10.1016/j.ejpb.2019.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
152 Parrott NJ, Yu LJ, Takano R, Nakamura M, Morcos PN. Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib. AAPS J 2016;18:1464-74. [PMID: 27450228 DOI: 10.1208/s12248-016-9957-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
153 Ranchon F, Vial T, Rioufol C, Hénin E, Falandry C, Freyer G, Trillet-Lenoir V, Le Tourneau C, You B. Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials. Crit Rev Oncol Hematol 2015;94:189-200. [PMID: 25638703 DOI: 10.1016/j.critrevonc.2014.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
154 Abu-Amna M, Bar-Sela G. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction? Cancer Chemother Pharmacol 2019;83:545-50. [PMID: 30547192 DOI: 10.1007/s00280-018-3758-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
155 Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19:1389-1400. [PMID: 24202392 DOI: 10.1038/nm.3388] [Cited by in Crossref: 580] [Cited by in F6Publishing: 550] [Article Influence: 64.4] [Reference Citation Analysis]
156 Chiang PC, Pang J, Liu J, Salphati L. An Investigation of Oral Exposure Variability and Formulation Strategy: A Case Study of PI3Kδ Inhibitor and Physiologically Based Pharmacokinetic Modeling in Beagle Dogs. J Pharm Sci 2018;107:466-75. [PMID: 28652157 DOI: 10.1016/j.xphs.2017.06.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
157 Liu S, Kurzrock R. Understanding Toxicities of Targeted Agents: Implications for Anti-tumor Activity and Management. Seminars in Oncology 2015;42:863-75. [DOI: 10.1053/j.seminoncol.2015.09.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
158 Ellenberger DJ, Miller DA, Kucera SU, Williams RO. Improved Vemurafenib Dissolution and Pharmacokinetics as an Amorphous Solid Dispersion Produced by KinetiSol® Processing. AAPS PharmSciTech 2018;19:1957-70. [DOI: 10.1208/s12249-018-0988-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
159 Zhu AZ, Ho MD, Gemski CK, Chuang BC, Liao M, Xia CQ. Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling. AAPS J 2016;18:1512-23. [PMID: 27600136 DOI: 10.1208/s12248-016-9972-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
160 Wang C, Wang M, Chen P, Wang J, Le Y. Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery. Pharmaceutics 2022;14:197. [DOI: 10.3390/pharmaceutics14010197] [Reference Citation Analysis]
161 Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2017;15:724-32. [PMID: 28645482 DOI: 10.1016/j.clgc.2017.05.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
162 Praphanwittaya P, Saokham P, Jansook P, Loftsson T. Aqueous solubility of kinase inhibitors: II the effect of hexadimethrine bromide on the dovitinib/γ-cyclodextrin complexation. Journal of Drug Delivery Science and Technology 2020;55:101463. [DOI: 10.1016/j.jddst.2019.101463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
163 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Meriggi F. Controversial link between proton pump inhibitors and anticancer agents: review of the literature. Tumori 2021;:3008916211025091. [PMID: 34159850 DOI: 10.1177/03008916211025091] [Reference Citation Analysis]
165 Venkatakrishnan K, Friberg LE, Ouellet D, Mettetal JT, Stein A, Trocóniz IF, Bruno R, Mehrotra N, Gobburu J, Mould DR. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther 2015;97:37-54. [PMID: 25670382 DOI: 10.1002/cpt.7] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
166 Yang KM, Shin IC, Park JW, Kim KS, Kim DK, Park K, Kim K. Nanoparticulation improves bioavailability of Erlotinib. Drug Dev Ind Pharm 2017;43:1557-65. [PMID: 28554216 DOI: 10.1080/03639045.2017.1326931] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
167 Truong DH, Le VKH, Pham TT, Dao AH, Pham TPD, Tran TH. Delivery of erlotinib for enhanced cancer treatment: An update review on particulate systems. Journal of Drug Delivery Science and Technology 2020;55:101348. [DOI: 10.1016/j.jddst.2019.101348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
168 Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther 2019;12:5467-84. [PMID: 31371986 DOI: 10.2147/OTT.S194870] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
169 Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev 2020;84:101966. [PMID: 32044644 DOI: 10.1016/j.ctrv.2020.101966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
170 Wang X, Liu C, Wang J, Fan Y, Wang Z, Wang Y. Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget 2017;8:58801-8. [PMID: 28938598 DOI: 10.18632/oncotarget.18522] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
171 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473-481. [PMID: 24981256 DOI: 10.1038/nrclinonc.2014.104] [Cited by in Crossref: 510] [Cited by in F6Publishing: 511] [Article Influence: 63.8] [Reference Citation Analysis]
172 Huo ZJ, Wang SJ, Wang ZQ, Zuo WS, Liu P, Pang B, Liu K. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation. Cancer Sci 2015;106:1429-37. [PMID: 26177628 DOI: 10.1111/cas.12737] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
173 Zhou X, Shi K, Hao Y, Yang C, Zha R, Yi C, Qian Z. Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy. Asian J Pharm Sci 2020;15:26-41. [PMID: 32175016 DOI: 10.1016/j.ajps.2019.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]